269 E. Grand Avenue
South San Francisco
106 articles with Cortexyme, Inc.
Cortexyme Assembles World Class Clinical Advisory Board to Support Its Alzheimer’s Disease Clinical Development Program
ortexyme, Inc., a clinical-stage pharmaceutical company developing therapeutics to alter the course of Alzheimer’s disease (AD) and other degenerative diseases, announced the formation of a new Clinical Advisory Board (CAB) in preparation for starting phase 2 clinical development in AD next year.
Alzheimer’s Company Cortexyme Closes $76 Million Series B Financing Round with Pfizer, Takeda and...
5/31/2018South San Francisco-based Cortexyme closed on a $76 million Series B financing round.
Cortexyme Completes $76 Million Series B Financing and Provides Update on Clinical Development Progress
Cortexyme has successfully completed key components of its phase 1 clinical development program for lead compound COR388
Cortexyme Initiates Phase I Clinical Development of COR388, a Promising Potential Treatment for Alzheimer’s and Other Degenerative Diseases
Cortexyme today announced the first cohort has been dosed in the initial trial of its phase 1 clinical development program for COR388, the company’s lead compound.